DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

根据InvestingPro数据，该股目前交易价格为$19.82，已有七位分析师下调了其盈利预期。这一变化是在Denali宣布其Phase 2/3 HEALEY试验的顶线数据未能达到主要终点后发生的。 Denali ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

分析师评论了Denali最近的股价下跌，将其归因于更广泛的市场趋势，而非公司特定消息。Denali的股价回调反映了XBI生物技术指数的走势，被认为是整体投资组合定位转变的一部分，在高利率环境下，较大的基金可能减少了生物技术领域的敞口。

Holland America Line is investing in its Alaska offerings by putting $70 million into the cruise line's popular Denali Lodge.

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...